195 related articles for article (PubMed ID: 16394090)
1. Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GH-deficient children.
Pilotta A; Mella P; Filisetti M; Felappi B; Prandi E; Parrinello G; Notarangelo LD; Buzi F
J Clin Endocrinol Metab; 2006 Mar; 91(3):1178-80. PubMed ID: 16394090
[TBL] [Abstract][Full Text] [Related]
2. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
Wassenaar MJ; Dekkers OM; Pereira AM; Wit JM; Smit JW; Biermasz NR; Romijn JA
J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188
[TBL] [Abstract][Full Text] [Related]
3. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
Binder G; Baur F; Schweizer R; Ranke MB
J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
[TBL] [Abstract][Full Text] [Related]
5. The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency.
Costalonga EF; Antonini SR; Guerra-Junior G; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2009 Feb; 94(2):588-95. PubMed ID: 18984657
[TBL] [Abstract][Full Text] [Related]
6. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome.
Braz AF; Costalonga EF; Montenegro LR; Trarbach EB; Antonini SR; Malaquias AC; Ramos ES; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2012 Apr; 97(4):E671-7. PubMed ID: 22278433
[TBL] [Abstract][Full Text] [Related]
7. Genetic predictors of long-term response to growth hormone (GH) therapy in children with GH deficiency and Turner syndrome: the influence of a SOCS2 polymorphism.
Braz AF; Costalonga EF; Trarbach EB; Scalco RC; Malaquias AC; Guerra-Junior G; Antonini SR; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1808-13. PubMed ID: 24905066
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children.
Carrascosa A; Audí L; Esteban C; Fernández-Cancio M; Andaluz P; Gussinyé M; Clemente M; Yeste D; Albisu MA
J Clin Endocrinol Metab; 2008 Jan; 93(1):147-53. PubMed ID: 17925340
[TBL] [Abstract][Full Text] [Related]
9. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study.
Audí L; Carrascosa A; Esteban C; Fernández-Cancio M; Andaluz P; Yeste D; Espadero R; Granada ML; Wollmann H; Fryklund L;
J Clin Endocrinol Metab; 2008 Jul; 93(7):2709-15. PubMed ID: 18445665
[TBL] [Abstract][Full Text] [Related]
10. Different relationships between the first 2 years on growth hormone treatment and the d3-growth hormone receptor polymorphism in short small-for-gestational-age (SGA) children.
Dörr HG; Bettendorf M; Hauffa BP; Mehls O; Rohrer T; Stahnke N; Pfäffle R; Ranke MB;
Clin Endocrinol (Oxf); 2011 Nov; 75(5):656-60. PubMed ID: 21623854
[TBL] [Abstract][Full Text] [Related]
11. Correlation between exon 3 polymorphism of growth hormone receptor gene and the responses to rhGH therapy.
Wei Y; Zheng R; Zhou Y; Wang J; Bao P
Int J Clin Exp Pathol; 2015; 8(6):7371-7. PubMed ID: 26261638
[TBL] [Abstract][Full Text] [Related]
12. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age.
Carrascosa A; Audí L; Fernández-Cancio M; Esteban C; Andaluz P; Vilaró E; Clemente M; Yeste D; Albisu MA; Gussinyé M
J Clin Endocrinol Metab; 2008 Mar; 93(3):764-70. PubMed ID: 18160465
[TBL] [Abstract][Full Text] [Related]
13. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency.
Barbosa EJ; Palming J; Glad CA; Filipsson H; Koranyi J; Bengtsson BA; Carlsson LM; Boguszewski CL; Johannsson G
J Clin Endocrinol Metab; 2009 Feb; 94(2):639-44. PubMed ID: 19050057
[TBL] [Abstract][Full Text] [Related]
14. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
15. The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients.
Carrascosa A; Esteban C; Espadero R; Fernández-Cancio M; Andaluz P; Clemente M; Audí L; Wollmann H; Fryklund L; Parodi L;
J Clin Endocrinol Metab; 2006 Sep; 91(9):3281-6. PubMed ID: 16804042
[TBL] [Abstract][Full Text] [Related]
16. MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism.
Boguszewski CL; Barbosa EJL; Svensson PA; Johannsson G; Glad CAM
Eur J Endocrinol; 2017 Dec; 177(6):R309-R321. PubMed ID: 28904008
[TBL] [Abstract][Full Text] [Related]
17. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism.
Tauber M; Ester W; Auriol F; Molinas C; Fauvel J; Caliebe J; Nugent T; Fryklund L; Ranke MB; Savage MO; Clark AJ; Johnston LB; Hokken-Koelega AC;
Clin Endocrinol (Oxf); 2007 Sep; 67(3):457-61. PubMed ID: 17555507
[TBL] [Abstract][Full Text] [Related]
18. The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy.
Adetunji OR; MacFarlane IA; Javadpour M; Alfirevic A; Pirmohamed M; Blair JC
Eur J Endocrinol; 2009 Oct; 161(4):541-6. PubMed ID: 19605543
[TBL] [Abstract][Full Text] [Related]
19. Growth Hormone (GH) receptor C.1319 G>T polymorphism, but not exon 3 retention or deletion is associated with better first-year growth response to GH therapy in patients with GH deficiency.
Wan L; Chen WC; Tsai Y; Kao YT; Hsieh YY; Lee CC; Tsai CH; Chen CP; Tsai FJ
Pediatr Res; 2007 Dec; 62(6):735-40. PubMed ID: 17957148
[TBL] [Abstract][Full Text] [Related]
20. Correlation of fl/d3 polymorphism of growth hormone receptor with the first- and second-year response to recombinant human growth hormone therapy in pre-pubertal Greek children with idiopathic isolated growth hormone deficiency.
Vassiliou G; Rousso I; Katzos G; Vavatsi-Christaki N; Tzimagiorgis G
J Endocrinol Invest; 2011 Sep; 34(8):609-14. PubMed ID: 20855935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
